Hisamitsu Pharmaceutical Co. Inc
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP X… Read more
Hisamitsu Pharmaceutical Co. Inc - Asset Resilience Ratio
Hisamitsu Pharmaceutical Co. Inc (HPX) has an Asset Resilience Ratio of 2.61% as of August 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Hisamitsu Pharmaceutical Co. Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hisamitsu Pharmaceutical Co. Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €9.16 Billion | 2.61% |
| Total Liquid Assets | €9.16 Billion | 2.61% |
Asset Resilience Insights
- Limited Liquidity: Hisamitsu Pharmaceutical Co. Inc maintains only 2.61% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hisamitsu Pharmaceutical Co. Inc Industry Peers by Asset Resilience Ratio
Compare Hisamitsu Pharmaceutical Co. Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma
KO:000220 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
Annual Asset Resilience Ratio for Hisamitsu Pharmaceutical Co. Inc (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Hisamitsu Pharmaceutical Co. Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-02-28 | 4.26% | €14.60 Billion | €343.07 Billion | +0.34pp |
| 2024-02-29 | 3.91% | €12.86 Billion | €328.78 Billion | -0.78pp |
| 2023-02-28 | 4.69% | €14.71 Billion | €313.92 Billion | +0.35pp |
| 2022-02-28 | 4.34% | €13.14 Billion | €302.86 Billion | -2.91pp |
| 2021-02-28 | 7.25% | €21.74 Billion | €299.86 Billion | -4.10pp |
| 2020-02-29 | 11.35% | €34.88 Billion | €307.40 Billion | +4.31pp |
| 2019-02-28 | 7.04% | €20.95 Billion | €297.51 Billion | +2.12pp |
| 2018-02-28 | 4.92% | €14.76 Billion | €299.91 Billion | -6.83pp |
| 2017-02-28 | 11.75% | €32.77 Billion | €278.82 Billion | +0.91pp |
| 2016-02-29 | 10.84% | €30.89 Billion | €284.95 Billion | +2.02pp |
| 2015-02-28 | 8.83% | €25.19 Billion | €285.44 Billion | +2.69pp |
| 2014-02-28 | 6.14% | €15.45 Billion | €251.85 Billion | -- |